The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Celecoxib API Market Research Report 2025
Synopsis
Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility. The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.
The global Celecoxib API market was valued at US$ 56 million in 2023 and is anticipated to reach US$ 82 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
This report aims to provide a comprehensive presentation of the global market for Celecoxib API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Celecoxib API.
Report Scope
The Celecoxib API market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Celecoxib API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Celecoxib API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Segment by Application
Pharmaceutical
Laboratory
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Celecoxib API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Celecoxib API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility. The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.
The global Celecoxib API market was valued at US$ 56 million in 2023 and is anticipated to reach US$ 82 million by 2030, witnessing a CAGR of 4.9% during the forecast period 2024-2030.
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
This report aims to provide a comprehensive presentation of the global market for Celecoxib API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Celecoxib API.
Report Scope
The Celecoxib API market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Celecoxib API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Celecoxib API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Segment by Application
Pharmaceutical
Laboratory
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Celecoxib API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Celecoxib API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Celecoxib API Market Overview
1.1 Product Overview and Scope of Celecoxib API
1.2 Celecoxib API Segment by Type
1.2.1 Global Celecoxib API Market Value Comparison by Type (2024-2030)
1.2.2 Standard grade Celecoxib API
1.2.3 Micronized Celecoxib API
1.3 Celecoxib API Segment by Application
1.3.1 Global Celecoxib API Market Value by Application: (2024-2030)
1.3.2 Pharmaceutical
1.3.3 Laboratory
1.4 Global Celecoxib API Market Size Estimates and Forecasts
1.4.1 Global Celecoxib API Revenue 2019-2030
1.4.2 Global Celecoxib API Sales 2019-2030
1.4.3 Global Celecoxib API Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Celecoxib API Market Competition by Manufacturers
2.1 Global Celecoxib API Sales Market Share by Manufacturers (2019-2024)
2.2 Global Celecoxib API Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Celecoxib API Average Price by Manufacturers (2019-2024)
2.4 Global Celecoxib API Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Celecoxib API, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Celecoxib API, Product Type & Application
2.7 Celecoxib API Market Competitive Situation and Trends
2.7.1 Celecoxib API Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Celecoxib API Players Market Share by Revenue
2.7.3 Global Celecoxib API Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Celecoxib API Retrospective Market Scenario by Region
3.1 Global Celecoxib API Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Celecoxib API Global Celecoxib API Sales by Region: 2019-2030
3.2.1 Global Celecoxib API Sales by Region: 2019-2024
3.2.2 Global Celecoxib API Sales by Region: 2025-2030
3.3 Global Celecoxib API Global Celecoxib API Revenue by Region: 2019-2030
3.3.1 Global Celecoxib API Revenue by Region: 2019-2024
3.3.2 Global Celecoxib API Revenue by Region: 2025-2030
3.4 North America Celecoxib API Market Facts & Figures by Country
3.4.1 North America Celecoxib API Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Celecoxib API Sales by Country (2019-2030)
3.4.3 North America Celecoxib API Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Celecoxib API Market Facts & Figures by Country
3.5.1 Europe Celecoxib API Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Celecoxib API Sales by Country (2019-2030)
3.5.3 Europe Celecoxib API Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Celecoxib API Market Facts & Figures by Country
3.6.1 Asia Pacific Celecoxib API Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Celecoxib API Sales by Country (2019-2030)
3.6.3 Asia Pacific Celecoxib API Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Celecoxib API Market Facts & Figures by Country
3.7.1 Latin America Celecoxib API Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Celecoxib API Sales by Country (2019-2030)
3.7.3 Latin America Celecoxib API Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Celecoxib API Market Facts & Figures by Country
3.8.1 Middle East and Africa Celecoxib API Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Celecoxib API Sales by Country (2019-2030)
3.8.3 Middle East and Africa Celecoxib API Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Celecoxib API Sales by Type (2019-2030)
4.1.1 Global Celecoxib API Sales by Type (2019-2024)
4.1.2 Global Celecoxib API Sales by Type (2025-2030)
4.1.3 Global Celecoxib API Sales Market Share by Type (2019-2030)
4.2 Global Celecoxib API Revenue by Type (2019-2030)
4.2.1 Global Celecoxib API Revenue by Type (2019-2024)
4.2.2 Global Celecoxib API Revenue by Type (2025-2030)
4.2.3 Global Celecoxib API Revenue Market Share by Type (2019-2030)
4.3 Global Celecoxib API Price by Type (2019-2030)
5 Segment by Application
5.1 Global Celecoxib API Sales by Application (2019-2030)
5.1.1 Global Celecoxib API Sales by Application (2019-2024)
5.1.2 Global Celecoxib API Sales by Application (2025-2030)
5.1.3 Global Celecoxib API Sales Market Share by Application (2019-2030)
5.2 Global Celecoxib API Revenue by Application (2019-2030)
5.2.1 Global Celecoxib API Revenue by Application (2019-2024)
5.2.2 Global Celecoxib API Revenue by Application (2025-2030)
5.2.3 Global Celecoxib API Revenue Market Share by Application (2019-2030)
5.3 Global Celecoxib API Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Celecoxib API Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Teva Pharmaceuticals
6.2.1 Teva Pharmaceuticals Corporation Information
6.2.2 Teva Pharmaceuticals Description and Business Overview
6.2.3 Teva Pharmaceuticals Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Teva Pharmaceuticals Celecoxib API Product Portfolio
6.2.5 Teva Pharmaceuticals Recent Developments/Updates
6.3 Viatris(Mylan)
6.3.1 Viatris(Mylan) Corporation Information
6.3.2 Viatris(Mylan) Description and Business Overview
6.3.3 Viatris(Mylan) Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Viatris(Mylan) Celecoxib API Product Portfolio
6.3.5 Viatris(Mylan) Recent Developments/Updates
6.4 ScinoPharm
6.4.1 ScinoPharm Corporation Information
6.4.2 ScinoPharm Description and Business Overview
6.4.3 ScinoPharm Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 ScinoPharm Celecoxib API Product Portfolio
6.4.5 ScinoPharm Recent Developments/Updates
6.5 Jiangxi Synergy
6.5.1 Jiangxi Synergy Corporation Information
6.5.2 Jiangxi Synergy Description and Business Overview
6.5.3 Jiangxi Synergy Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Jiangxi Synergy Celecoxib API Product Portfolio
6.5.5 Jiangxi Synergy Recent Developments/Updates
6.6 Jiangsu Hengrui Medicine
6.6.1 Jiangsu Hengrui Medicine Corporation Information
6.6.2 Jiangsu Hengrui Medicine Description and Business Overview
6.6.3 Jiangsu Hengrui Medicine Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Jiangsu Hengrui Medicine Celecoxib API Product Portfolio
6.6.5 Jiangsu Hengrui Medicine Recent Developments/Updates
6.7 Jiangsu Chiatai Qingjiang
6.6.1 Jiangsu Chiatai Qingjiang Corporation Information
6.6.2 Jiangsu Chiatai Qingjiang Description and Business Overview
6.6.3 Jiangsu Chiatai Qingjiang Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Jiangsu Chiatai Qingjiang Celecoxib API Product Portfolio
6.7.5 Jiangsu Chiatai Qingjiang Recent Developments/Updates
6.8 Hisun Pharmaceutical Nantong
6.8.1 Hisun Pharmaceutical Nantong Corporation Information
6.8.2 Hisun Pharmaceutical Nantong Description and Business Overview
6.8.3 Hisun Pharmaceutical Nantong Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Hisun Pharmaceutical Nantong Celecoxib API Product Portfolio
6.8.5 Hisun Pharmaceutical Nantong Recent Developments/Updates
6.9 Aurobindo Pharma
6.9.1 Aurobindo Pharma Corporation Information
6.9.2 Aurobindo Pharma Description and Business Overview
6.9.3 Aurobindo Pharma Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Aurobindo Pharma Celecoxib API Product Portfolio
6.9.5 Aurobindo Pharma Recent Developments/Updates
6.10 Punjab Chemicals
6.10.1 Punjab Chemicals Corporation Information
6.10.2 Punjab Chemicals Description and Business Overview
6.10.3 Punjab Chemicals Celecoxib API Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Punjab Chemicals Celecoxib API Product Portfolio
6.10.5 Punjab Chemicals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Celecoxib API Industry Chain Analysis
7.2 Celecoxib API Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Celecoxib API Production Mode & Process
7.4 Celecoxib API Sales and Marketing
7.4.1 Celecoxib API Sales Channels
7.4.2 Celecoxib API Distributors
7.5 Celecoxib API Customers
8 Celecoxib API Market Dynamics
8.1 Celecoxib API Industry Trends
8.2 Celecoxib API Market Drivers
8.3 Celecoxib API Market Challenges
8.4 Celecoxib API Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
